LEIDOS BIOMEDICAL RESEARCH INC
Federal contract award, Leidos, $89,563,956
Key CONT_AWD_75N91020F00009_7529_75N91019D00024_7529. First seen by this system September 5, 2026 through the historical sweep, new to the watchlist, public 341 days before this system saw it. One version on record.
Cite this row
On this site https://evidence.ourrevolution.media/filings/leidos/CONT_AWD_75N91020F00009_7529_75N91019D00024_7529
Observed 2026-09-05, version 1, retrieved 2026-09-05T00:54:28Z
Content hash
ee82cffe6b270962795e459a4602f0c097013991667df6d5f5db61eb3201851fThe source record can change after this date; the key, hash and retrieval time name exactly the response this system stored. See license and citation.
Versions
| Version | Amount | Change | Occurred | Published | Retrieved | How it arrived | Content hash |
|---|---|---|---|---|---|---|---|
| 1 current | $89,563,956 | first version | April 1, 2020 | September 29, 2025 | 2026-09-05T00:54:28Z | historical sweep | ee82cffe6b27 |
Archived copy
https://web.archive.org/web/20261010172247/https://www.usaspending.gov/award/CONT_AWD_75N91020F00009_7529_75N91019D00024_7529 captured by this system, October 10, 2026
What the amount is made of
13 recorded actions, so the amount is the award's current total across all of them. 5 of them obligated money. Measured 2026-10-13, when USAspending reported a total obligation of $89,563,956.
| Action date | Modification | Type | Obligated | Description as recorded |
|---|---|---|---|---|
| September 29, 2025 | P00012 | OTHER ADMINISTRATIVE ACTION | +$5,946,332 | NIAID DCR COVID-19 TRIALS - COVID-19 - NCI FEDERALLY FUNDED RESEARCH AND DEVELOPMENT CENTER (FFRDC) CONTRACT |
| April 24, 2025 | P00011 | TERMINATE FOR CONVENIENCE (COMPLETE OR PARTIAL) | no money | EOI::IMPLEMENTING THE PRESIDENTS DEPARTMENT OF GOVERNMENT EFFICIENCY COST EFFICIENCY INITIATIVE (MARCH 19, 2025)::EOI |
| September 25, 2024 | P00010 | OTHER ADMINISTRATIVE ACTION | +$13,721,004 | ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II: I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS |
| August 21, 2024 | P00009 | OTHER ADMINISTRATIVE ACTION | no money | ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II: I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS |
| May 31, 2024 | P00008 | OTHER ADMINISTRATIVE ACTION | no money | ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II: I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS |
| October 31, 2023 | P00007 | OTHER ADMINISTRATIVE ACTION | no money | ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II: I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS |
| April 21, 2022 | P00006 | FUNDING ONLY ACTION | no money | ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II: I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS |
| March 4, 2022 | P00005 | OTHER ADMINISTRATIVE ACTION | no money | ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II: I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS |
| February 8, 2022 | P00004 | EXERCISE AN OPTION | +$2,536,808 | ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II: I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS |
| November 20, 2020 | P00003 | OTHER ADMINISTRATIVE ACTION | no money | ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II: I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS |
| October 27, 2020 | P00002 | OTHER ADMINISTRATIVE ACTION | no money | ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II: I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS |
| July 30, 2020 | P00001 | DEFINITIZE LETTER CONTRACT | +$33,788,063 | ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II: I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS |
| April 1, 2020 | base | not on file | +$33,571,749 | ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II: I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS |
Last refreshed November 4, 2026 at 2:31 PM UTC.